ASCO: GenFleet’s KRAS G12C/EGFR Combo Sets Sail In First-Line NSCLC

IO, Chemo-Free Strategy

 
• By Dexter Jie Yan
set sail
GenFleet sets sail in first-line KRAS G12C-mutated NSCLC with novel combo strategy excluding PD-1s • Source: Shutterstock

More from China

More from Focus On Asia